{"id":25971,"date":"2026-03-05T14:30:44","date_gmt":"2026-03-05T14:30:44","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/25971\/"},"modified":"2026-03-05T14:30:44","modified_gmt":"2026-03-05T14:30:44","slug":"is-roche-holding-swxrog-still-attractively-priced-after-strong-three-year-share-gains","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/25971\/","title":{"rendered":"Is Roche Holding (SWX:ROG) Still Attractively Priced After Strong Three Year Share Gains?"},"content":{"rendered":"\n

Make better investment decisions<\/a> with Simply Wall St’s easy, visual tools that give you a competitive edge.<\/p>\n

If you are wondering whether Roche Holding’s current share price reflects its true worth, this article will walk through the numbers in a clear and practical way.<\/p>\n

The stock most recently closed at CHF 358.80, with returns of 1.2% over 30 days and 10.2% year to date, while the 1 year and 3 year figures sit at 22.3% and 50.7% respectively.<\/p>\n

Recent news around Roche has centered on its position as a major global pharmaceuticals and biotech group, with investors watching how its product pipeline and diagnostics franchise feed into long term expectations. Headlines have also highlighted how large healthcare names can be treated as relatively defensive, which can influence how quickly sentiment shifts when new information emerges.<\/p>\n

On Simply Wall St’s 6 point valuation checklist, Roche Holding scores 5 out of 6, which supports a closer look at how different valuation methods compare and hints at an even richer way to think about fair value that we will come back to at the end of the article.<\/p>\n

Find out why Roche Holding’s 22.3% return over the last year is lagging behind its peers.<\/a><\/p>\n

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today to reflect risk and the time value of money.<\/p>\n

For Roche Holding, the latest twelve month Free Cash Flow (FCF) is about CHF 13.6b. Analysts have provided FCF projections out to 2030, with Simply Wall St extending these further based on its 2 Stage Free Cash Flow to Equity model. By 2030, projected FCF is CHF 22.0b, with intermediate annual estimates between 2026 and 2035 ranging from roughly CHF 15.6b to CHF 25.8b before discounting.<\/p>\n

When these projected cash flows are discounted back and combined, the model arrives at an estimated intrinsic value of CHF 875.58 per share. Compared with the recent share price of CHF 358.80, this implies the stock is around 59.0% undervalued on this DCF view.<\/p>\n

Result: UNDERVALUED<\/p>\n

Our Discounted Cash Flow (DCF) analysis suggests Roche Holding is undervalued by 59.0%. Track this in your watchlist<\/a> or portfolio<\/a>, or discover 227 more high quality undervalued stocks<\/a>.<\/p>\n

\"ROG<\/a> ROG Discounted Cash Flow as at Mar 2026 <\/p>\n

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Roche Holding.<\/a><\/p>\n

For a profitable company like Roche Holding, the P\/E ratio is a straightforward way to connect the share price with the earnings that support it. Many investors therefore lean on it as a primary cross check on value.<\/p>\n

What counts as a \u201cnormal\u201d P\/E depends on how quickly earnings are expected to grow and how risky those earnings look. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk tends to pull a fair P\/E down.<\/p>\n

Roche Holding currently trades on a P\/E of 22.16x, which sits slightly above the Pharmaceuticals industry average of 21.22x and well below the peer group average of 54.85x. Simply Wall St\u2019s Fair Ratio for Roche, at 42.62x, is a proprietary estimate of what the P\/E could be given factors such as earnings growth, profit margins, industry, market cap and company specific risks.<\/p>\n

This Fair Ratio is more tailored than a simple comparison with peers or the industry, because it tries to match Roche\u2019s own characteristics rather than averaging across very different businesses. With the current P\/E at 22.16x versus a Fair Ratio of 42.62x, Roche Holding appears undervalued on this multiple based view.<\/p>\n

Result: UNDERVALUED<\/p>\n

\"SWX:ROG<\/a> SWX:ROG P\/E Ratio as at Mar 2026 <\/p>\n

P\/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 99 top founder-led companies<\/a>.<\/p>\n

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple framework on Simply Wall St\u2019s Community page where you set out your story for Roche Holding, link that story to your own revenue, earnings and margin assumptions, and see what fair value falls out of those numbers. A Narrative connects three pieces in one place: what you think is happening with Roche\u2019s pipeline, diagnostics and risks; what that means for the financials over time; and the fair value that results, which you can then compare with the current share price to decide whether the stock looks attractive or expensive on your view. Because Narratives sit on the platform used by millions of investors, they are easy to create, compare and update when new information such as earnings, clinical trial news or pricing headlines feeds into your thesis. For Roche, one investor might plug in assumptions that point to a fair value around CHF 230, while another might build a more optimistic Narrative that supports a fair value closer to CHF 430. Seeing that spread helps you decide where your own view fits and how confident you feel about acting on it.<\/p>\n

For Roche Holding, here are previews of two leading Roche Holding Narratives:<\/p>\n

\ud83d\udc02 Roche Holding Bull Case<\/p>\n

Fair value in this bullish Narrative: CHF 430.01 per share<\/p>\n

Implied undervaluation vs last close of CHF 358.80: about 16.5%<\/p>\n

Narrative revenue growth assumption: 6.77%<\/p>\n

Centers on Roche as a global pharma and diagnostics group with both divisions contributing to a broad base of cash flow and earnings.<\/p>\n

Highlights a wide set of potential drug catalysts in obesity, oncology and neurology, alongside a series of upcoming Phase III readouts and a long history of cash returns to shareholders.<\/p>\n

Builds a fair value mainly from a DCF and P\/E range that points to a higher price than today, while still flagging clinical, competitive and patent related risks.<\/p>\n

\ud83d\udc3b Roche Holding Bear Case<\/p>\n

Fair value in this more cautious Narrative: CHF 358.45 per share<\/p>\n

Implied overvaluation vs last close of CHF 358.80: about 0.1%<\/p>\n

Narrative revenue growth assumption: 2.71%<\/p>\n

Frames Roche as a diversified pharma and diagnostics business where pipeline execution, automation and digital diagnostics are important to future earnings and margins.<\/p>\n

Leans on consensus assumptions for moderate revenue growth and higher profit margins by 2028, with fair value close to the current share price.<\/p>\n

Spells out risks around China pricing, patent expiries, biosimilar competition, regulatory outcomes and diagnostics execution, suggesting a more balanced risk reward set up.<\/p>\n

These two Narratives give you a quick sense of how different investors connect the same set of Roche facts to very different fair value views. If you feel one of them lines up with your own thinking, you can use it as a starting point to refine your assumptions rather than as a final answer.<\/p>\n

Curious how numbers become stories that shape markets? Explore Community Narratives<\/a><\/p>\n

Do you think there’s more to the story for Roche Holding? Head over to our Community to see what others are saying!<\/a><\/p>\n

\"SWX:ROG<\/a> SWX:ROG 1-Year Stock Price Chart <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include ROG.SW<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. If…\n","protected":false},"author":2,"featured_media":18683,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[962,1103,1104,134,994,842],"class_list":{"0":"post-25971","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-chf","9":"tag-dcf","10":"tag-fair-value","11":"tag-roche","12":"tag-roche-holding","13":"tag-share-price"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116177051508376510","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/25971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=25971"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/25971\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/18683"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=25971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=25971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=25971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}